Exosome-based topical product for skin repair and regeneration
Innovative exosome-based topical product designed to repair and regenerate skin while reducing scars. Utilizes nano-sized extracellular vesicles to encapsulate bioactive molecules for enhanced skin healing.
Overview
This exosome-based topical product represents a pioneering advancement in skin repair and regeneration. Utilizing nano-sized extracellular vesicles, or exosomes, the product is designed to significantly improve skin healing and reduce scar appearance. By harnessing the natural regenerative capabilities of exosomes and enhancing them with bioactive molecules, this solution offers a promising approach to skin care and wound healing.
Technical specifications
Key features:
- Exosomes are nano-sized vesicles (30-150 nm) with a lipid bilayer membrane.
- Capable of encapsulating bioactive molecules and naturally-derived compounds.
- Demonstrated efficacy in cell culture and animal models for accelerated wound healing and scar reduction.
- Potential for future enhancement to lighten scars, reduce inflammation, and provide antimicrobial benefits by encapsulating suitable compounds.
Technology readiness level
The technology is currently at TRL 4, having been validated in laboratory settings and animal models. Future plans include further testing in additional animal models to expand its applications, such as scar lightening and anti-inflammatory properties.
About University of Waterloo
University of Waterloo is a public research university in Ontario, Canada, known for an entrepreneurial, STEM‑driven culture. A globally recognized co‑op program places students with employers year‑round, creating direct talent pipelines and de‑risked pathways into sponsored research and contract development. An adjacent research and technology park hosts corporate R&D alongside faculty labs, and the campus sits within the Toronto–Waterloo innovation corridor for ready access to partners, investors, and scale‑up resources. Research is supported by competitive federal funding from Canada’s Tri‑Council agencies (NSERC, CIHR, SSHRC) and international programs. A creator‑owned IP policy and a dedicated tech transfer office enable flexible agreements, licensing, and spinouts.
delivered to your inbox.